Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma

Ayoub Saaid; Matteo Monticelli; Alessia Andrea Ricci; Giulia Orlando; Cristina Botta; Pietro Zeppa; Andrea Bianconi; Simona Osella-Abate; Francesco Bruno; Alessia Pellerino; Roberta Rudà; Paola Cassoni; Diego Garbossa; Fabio Cofano; Luca Bertero

doi:10.3390/genes13081439

Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma

Genes (Basel). 2022 Aug 12;13(8):1439. doi: 10.3390/genes13081439.

Authors

Affiliations

¹ Neurosurgery Unit, Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10126 Turin, Italy.
² Neurosurgery Unit, Department of Neuroscience and Rehabilitation, University of Ferrara, 44100 Ferrara, Italy.
³ Pathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
⁴ Pathology Unit, Department of Oncology, University of Turin, 10126 Turin, Italy.
⁵ Neuro-Oncology Unit, Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10126 Turin, Italy.
⁶ Department of Neurology, Castelfranco and Treviso Hospitals, 31100 Treviso, Italy.

Abstract

The G105G SNP (rs11554137) in the IDH1 gene is observed in about 10-15% of patients with a diffuse glioma. Data regarding its impact on gliomas are poor and partially conflicting, possibly due to the evolving classification of CNS tumors. The aim of this study was to investigate the G105G SNP prognostic significance in a homogenous cohort of IDH-wildtype glioblastomas, in agreement with the 2021 WHO classification. The study analyzed 211 patients by collecting several clinico-pathological and molecular characteristics, including the age, lesion localization, number of involved lobes, type of surgical treatment, disease outcome and MGMT promoter methylation status. PFS and DSS curves were plotted according to the Kaplan-Meier method and statistical analyses were performed using parametric and non-parametric tests. A total of 32 patients out of 211 (15.2%) were found to be G105G SNP carriers. No significant impact of the IDH1 G105G SNP on patients' outcomes was observed in terms of PFS and DSS, while MGMT promoter methylation and gross total resection resulted as key prognostic factors in our cohort as expected. No prognostic impact of the IDH1 G105G SNP was detected in this strict cohort of IDH-wildtype glioblastomas. Analysis of larger cohorts is warranted to address the sample size limitations.

Keywords: IDH1; SNP; glioblastoma; prognosis; rs11554137.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Brain Neoplasms* / genetics
Brain Neoplasms* / pathology
Glioblastoma* / genetics
Glioma* / genetics
Humans
Isocitrate Dehydrogenase / genetics
Mutation
Polymorphism, Single Nucleotide*
Prognosis

Substances

Isocitrate Dehydrogenase
IDH1 protein, human

Grants and funding

This research was funded by Ministero dell’Istruzione, dell’Università e della Ricerca—MIUR project “Dipartimenti di Eccellenza 2018–2022” (Project n° D15D18000410001) and Rete Oncologica del Piemonte e Valle d’Aosta.